Source: City of Hope National Medical Center
Date: June 2, 2010
Summary:
DUARTE, Calif., — City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor.
